Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ITOSNASDAQ:MGTXNASDAQ:OCSNASDAQ:ORIC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITOSiTeos Therapeutics$10.03-0.3%$6.92$4.80▼$18.13$383.89M1.39635,220 shs3.77 million shsMGTXMeiraGTx$5.36+5.1%$5.86$3.85▼$8.75$430.76M1.3362,829 shs340,916 shsOCSOculis$19.50-0.5%$17.89$10.79▼$23.08$851.41M0.2744,001 shs12,230 shsORICORIC Pharmaceuticals$7.97+33.5%$5.35$3.90▼$14.67$566.57M1.37720,554 shs14.45 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITOSiTeos Therapeutics-0.30%+15.42%+46.42%+38.15%-42.16%MGTXMeiraGTx+5.10%+5.93%-22.32%-24.82%+7.20%OCSOculis-0.51%+8.64%+10.98%-0.41%+63.45%ORICORIC Pharmaceuticals+33.50%+33.95%+40.81%-0.75%-5.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationITOSiTeos Therapeutics3.1712 of 5 stars4.12.00.00.02.33.30.6MGTXMeiraGTx4.4932 of 5 stars3.52.00.04.82.12.51.9OCSOculis2.1629 of 5 stars3.53.00.00.02.70.00.6ORICORIC Pharmaceuticals3.71 of 5 stars3.50.00.04.33.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceITOSiTeos Therapeutics 2.14Hold$15.8658.10% UpsideMGTXMeiraGTx 3.00Buy$24.00347.76% UpsideOCSOculis 3.00Buy$31.5061.54% UpsideORICORIC Pharmaceuticals 3.00Buy$19.17140.49% UpsideCurrent Analyst Ratings BreakdownLatest ITOS, OCS, ORIC, and MGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025ORICORIC PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$20.005/28/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$13.00 ➝ $12.005/28/2025ITOSiTeos TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$10.00 ➝ $12.005/14/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$16.00 ➝ $13.005/14/2025ITOSiTeos TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$12.005/14/2025ITOSiTeos TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$16.00 ➝ $12.005/14/2025ITOSiTeos TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/14/2025ITOSiTeos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/14/2025ITOSiTeos TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$47.00 ➝ $9.005/14/2025MGTXMeiraGTxChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $35.005/13/2025ITOSiTeos TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$15.00 ➝ $8.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookITOSiTeos Therapeutics$35M10.97N/AN/A$16.08 per share0.62MGTXMeiraGTx$34.51M12.48N/AN/A$2.17 per share2.47OCSOculis$980K868.78N/AN/A$2.87 per share6.79ORICORIC PharmaceuticalsN/AN/AN/AN/A$3.42 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateITOSiTeos Therapeutics-$112.64M-$3.04N/AN/AN/AN/A-20.11%-17.50%8/14/2025 (Estimated)MGTXMeiraGTx-$84.03M-$2.32N/A14.110.37-633.05%-146.38%-53.05%8/11/2025 (Estimated)OCSOculis-$98.92M-$2.64N/AN/AN/A-8,043.28%-71.31%-56.85%N/AORICORIC Pharmaceuticals-$100.70M-$1.87N/AN/AN/AN/A-44.54%-40.72%8/11/2025 (Estimated)Latest ITOS, OCS, ORIC, and MGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MGTXMeiraGTx-$0.38-$0.51-$0.13-$0.51$4.44 million$1.93 million5/8/2025Q1 2025OCSOculis-$0.51-$0.77-$0.26-$0.77$0.22 million$0.32 million5/5/2025Q1 2025ORICORIC Pharmaceuticals-$0.51-$0.42+$0.09-$0.42N/AN/A4/28/2025Q1 2025ITOSiTeos Therapeutics-$0.94-$0.80+$0.14-$0.80$9.35 millionN/A3/13/2025Q4 2024MGTXMeiraGTx-$0.48-$0.50-$0.02-$0.50$1.50 million$21.39 million3/11/2025Q4 2024OCSOculis-$0.48-$0.76-$0.28-$0.76$0.21 millionN/A3/5/2025Q4 2024ITOSiTeos Therapeutics-$1.14-$1.01+$0.13-$1.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthITOSiTeos TherapeuticsN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/AORICORIC PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioITOSiTeos TherapeuticsN/A14.8014.80MGTXMeiraGTx0.862.342.34OCSOculis0.014.024.02ORICORIC PharmaceuticalsN/A10.5613.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipITOSiTeos Therapeutics97.16%MGTXMeiraGTx67.48%OCSOculis22.30%ORICORIC Pharmaceuticals95.05%Insider OwnershipCompanyInsider OwnershipITOSiTeos Therapeutics12.50%MGTXMeiraGTx7.50%OCSOculisN/AORICORIC Pharmaceuticals6.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableITOSiTeos Therapeutics9038.27 million31.97 millionOptionableMGTXMeiraGTx30080.37 million71.59 millionOptionableOCSOculis243.66 millionN/ANot OptionableORICORIC Pharmaceuticals8071.09 million67.09 millionOptionableITOS, OCS, ORIC, and MGTX HeadlinesRecent News About These CompaniesOric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer TrialMay 30 at 12:52 AM | msn.comORIC Pharmaceuticals shares surge on promising trial dataMay 29 at 2:05 PM | in.investing.comORIC Pharmaceuticals Shares Rally 20% on Encouraging Cancer Drug Trial and Funding UpdateMay 29 at 2:05 PM | msn.comORIC Stock Surges on Upbeat Initial Data From Prostate Cancer StudyMay 29 at 12:55 PM | zacks.comORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises CapitalMay 29 at 11:15 AM | benzinga.comORIC® Pharmaceuticals Announces $125 Million Private Placement FinancingMay 29 at 9:03 AM | tmcnet.comOric Pharma Shares Rise 18% on Cancer Drug Results, Private Placement NewsMay 29 at 9:03 AM | marketwatch.comORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 TrialsMay 29 at 12:57 AM | insidermonkey.comORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPCMay 28 at 4:18 PM | globenewswire.comORIC® Pharmaceuticals Announces $125 Million Private Placement FinancingMay 28 at 4:18 PM | globenewswire.comORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination ...May 27 at 7:05 PM | bakersfield.comORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 27 at 4:30 PM | globenewswire.comORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPCMay 27 at 8:00 AM | globenewswire.comFrazier Life Sciences Management L.P. Sells 254,617 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)May 23, 2025 | marketbeat.comCantor Fitzgerald maintains Overweight on ORIC sharesMay 22, 2025 | uk.investing.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Buy" by BrokeragesMay 19, 2025 | marketbeat.comSphera Funds Management LTD. Acquires 144,817 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)May 18, 2025 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by NEA Management Company LLCMay 15, 2025 | marketbeat.comDimensional Fund Advisors LP Acquires 103,237 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)May 13, 2025 | marketbeat.comBalyasny Asset Management L.P. Purchases 424,194 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)May 11, 2025 | marketbeat.comQ2 EPS Forecast for ORIC Pharmaceuticals Raised by AnalystMay 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumAdvance Auto Parts Jumps on Surprise Earnings BeatBy Chris Markoch | May 23, 2025View Advance Auto Parts Jumps on Surprise Earnings BeatITOS, OCS, ORIC, and MGTX Company DescriptionsiTeos Therapeutics NASDAQ:ITOS$10.03 -0.03 (-0.30%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$10.08 +0.05 (+0.46%) As of 04:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.MeiraGTx NASDAQ:MGTX$5.36 +0.26 (+5.10%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$5.68 +0.32 (+5.88%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Oculis NASDAQ:OCS$19.50 -0.10 (-0.51%) As of 05/29/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.ORIC Pharmaceuticals NASDAQ:ORIC$7.97 +2.00 (+33.50%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$7.81 -0.16 (-2.01%) As of 05:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
